Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Timothy Kanter

Internal Medicine Bronx, NY Medical Doctor

NPI 1083706535 CMS profile 275690

1650 Selwyn Ave Fl 10, Bronx, NY 10457

Open in the dashboard

General payments

$630,270

703 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Timothy Kanter of Bronx, NY is reported in the CMS Open Payments database as having received $630,270 across 703 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $84 1
2022 General $146,496 146
2021 General $132,427 139
2020 General $104,755 113
2019 General $246,508 304

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Kanter
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Timothy Kanter were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Timothy Kanter Internal Medicine median Middle half National median
2019 $246,508 $159 $48–$570 $163
2020 $104,755 $119 $33–$402 $114
2021 $132,427 $135 $37–$521 $132
2022 $146,496 $141 $42–$496 $149
2023 $84 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. ViiV Healthcare Company $408,975 349 payments
  2. Gilead Sciences, Inc. $93,891 136 payments
  3. Merck Sharp & Dohme Corporation $69,239 106 payments
  4. Janssen Products, LP $51,777 50 payments
  5. Theratechnologies Inc. $3,374 8 payments
  6. Janssen Biotech, Inc. $1,167 38 payments
  7. GlaxoSmithKline, LLC. $975 9 payments
  8. Sanofi-Aventis U.S. LLC $300 1 payment
  9. Napo Pharmaceuticals Inc $242 2 payments
  10. Janssen Scientific Affairs, LLC $185 2 payments
  11. Other $145 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $556,845 222 payments
  2. Travel and Lodging $47,392 179 payments
  3. Food and Beverage $18,793 296 payments
  4. Consulting Fee $7,240 6 payments
Products named General payments · program years 2019–2023
  1. DOVATO $291,599 246 payments
  2. CABENUVA $72,241 50 payments
  3. Biktarvy $54,237 65 payments
  4. SYMTUZA $52,910 85 payments
  5. DELSTRIGO $42,056 62 payments
  6. APRETUDE $33,605 23 payments
  7. PIFELTRO $20,100 33 payments
  8. ISENTRESS $4,478 10 payments
  9. TIVICAY $4,429 9 payments
  10. TROGARZO $1,374 6 payments
  11. Other $1,507 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

703 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record